Liquid biopsies may guide lung cancer treatment timing
NCT ID NCT02856893
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 20 times
Summary
This phase 2 trial studies the best strategy for giving the drug osimertinib to people with advanced EGFR-mutant non-small cell lung cancer. It compares starting osimertinib right away versus using it after another drug stops working. The study also checks if blood tests (liquid biopsies) can detect cancer progression as well as standard scans. 156 adults with stage IV lung cancer are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Assistance Publique - Hopitaux de Marseille - Hopital Nord
Marseille, France
-
CHU Toulouse - Hopital Larrey
Toulouse, France
-
CHU de Brest
Brest, France
-
Centre Francois Baclesse
Caen, France
-
Centre Hopitalier Intercommunal De Creteil
Créteil, France
-
Centre Paul Strauss
Strasbourg, France
-
Gustave Roussy
Villejuif, France
-
Hospital Clinic Universitari de Barcelona
Barcelona, Spain
-
Hospital De La Santa Creu I Sant Pau
Barcelona, Spain
-
Hospital Universitario 12 De Octubre
Madrid, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, Spain
-
Institut Bergonie
Bordeaux, France
-
Institut Catala d'Oncologia - ICO Badalona - Hospital De Mataro
Mataró, Spain
-
Institut Jules Bordet
Brussels, Bruxelles Région, 1070, Belgium
-
Institut Paoli-Calmettes
Marseille, France
-
Institut de Cancerologie de Lorraine
Vandœuvre-lès-Nancy, France
-
King Hussein Cancer Center
Amman, Jordan
-
Medical University of Gdansk
Gdansk, Poland
-
The Institute Of Oncology
Ljubljana, Slovenia
-
University Clinic Golnik
Golnik, Slovenia
-
University Hospital A Coruna-Hospital Teresa Herrera
A Coruña, Spain
-
Vall d'Hebron Institut d'Oncologia
Barcelona, Spain
-
Virgen del Rocio University Hospital
Seville, Spain
Conditions
Explore the condition pages connected to this study.